Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Promoter methylation and the detection of breast cancer.

Brooks J, Cairns P, Zeleniuch-Jacquotte A.

Cancer Causes Control. 2009 Nov;20(9):1539-50. doi: 10.1007/s10552-009-9415-y. Review.

2.

BRCA1 promoter hypermethylation signature for early detection of breast cancer in the Vietnamese population.

Truong PK, Lao TD, Doan TP, Le TA.

Asian Pac J Cancer Prev. 2014;15(22):9607-10.

3.

Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.

Dulaimi E, Hillinck J, Ibanez de Caceres I, Al-Saleem T, Cairns P.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6189-93.

4.

Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening.

Kloten V, Becker B, Winner K, Schrauder MG, Fasching PA, Anzeneder T, Veeck J, Hartmann A, Knüchel R, Dahl E.

Breast Cancer Res. 2013 Jan 15;15(1):R4. doi: 10.1186/bcr3375.

5.

DNA methylation in pre-diagnostic serum samples of breast cancer cases: results of a nested case-control study.

Brooks JD, Cairns P, Shore RE, Klein CB, Wirgin I, Afanasyeva Y, Zeleniuch-Jacquotte A.

Cancer Epidemiol. 2010 Dec;34(6):717-23. doi: 10.1016/j.canep.2010.05.006.

6.

Protein expression and methylation of MGMT, a DNA repair gene and their correlation with clinicopathological parameters in invasive ductal carcinoma of the breast.

Asiaf A, Ahmad ST, Malik AA, Aziz SA, Rasool Z, Masood A, Zargar MA.

Tumour Biol. 2015 Aug;36(8):6485-96. doi: 10.1007/s13277-015-3339-9. Epub 2015 Mar 29.

PMID:
25820821
7.

Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients.

Mirza S, Sharma G, Prasad CP, Parshad R, Srivastava A, Gupta SD, Ralhan R.

Life Sci. 2007 Jul 4;81(4):280-7. Epub 2007 May 25.

PMID:
17599361
8.

Promoter hypermethylation in sentinel lymph nodes as a marker for breast cancer recurrence.

Carraway HE, Wang S, Blackford A, Guo M, Powers P, Jeter S, Davidson NE, Argani P, Terrell K, Herman JG, Lange JR.

Breast Cancer Res Treat. 2009 Mar;114(2):315-25. doi: 10.1007/s10549-008-0004-7. Epub 2008 Apr 11.

9.

Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling.

Chung W, Kwabi-Addo B, Ittmann M, Jelinek J, Shen L, Yu Y, Issa JP.

PLoS One. 2008 Apr 30;3(4):e2079. doi: 10.1371/journal.pone.0002079. Erratum in: PLoS ONE. 2008;3(5). doi: 10.1371/annotation/2548989f-1f13-4ea5-8af8-62420b0a590e.

10.

Validation of DNA promoter hypermethylation biomarkers in breast cancer--a short report.

de Groot JS, Pan X, Meeldijk J, van der Wall E, van Diest PJ, Moelans CB.

Cell Oncol (Dordr). 2014 Aug;37(4):297-303. doi: 10.1007/s13402-014-0189-1. Epub 2014 Aug 16.

PMID:
25123395
11.

Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA.

Ahmed IA, Pusch CM, Hamed T, Rashad H, Idris A, El-Fadle AA, Blin N.

Cancer Genet Cytogenet. 2010 Jun;199(2):96-100. doi: 10.1016/j.cancergencyto.2010.02.007.

PMID:
20471512
12.

DNA methylation in cancer: a gene silencing mechanism and the clinical potential of its biomarkers.

Fukushige S, Horii A.

Tohoku J Exp Med. 2013 Mar;229(3):173-85. Review.

13.

Aberrant promoter hypermethylation and genomic hypomethylation in tumor, adjacent normal tissues and blood from breast cancer patients.

Cho YH, Yazici H, Wu HC, Terry MB, Gonzalez K, Qu M, Dalay N, Santella RM.

Anticancer Res. 2010 Jul;30(7):2489-96.

14.

DNA promoter hypermethylation profiles in breast duct fluid.

Twelves D, Nerurkar A, Osin P, Dexter T, Ward A, Gui GP, Isacke CM.

Breast Cancer Res Treat. 2013 Jun;139(2):341-50. doi: 10.1007/s10549-013-2544-8. Epub 2013 May 15.

PMID:
23674191
15.

Aberrantly methylated DNA as a biomarker in breast cancer.

Kristiansen S, Jørgensen LM, Guldberg P, Sölétormos G.

Int J Biol Markers. 2013 Apr-Jun;28(2):141-50. doi: 10.5301/jbm.5000009. Epub 2013 Apr 2.

PMID:
23564623
16.

Aberrant promoter CpG methylation and its translational applications in breast cancer.

Xiang TX, Yuan Y, Li LL, Wang ZH, Dan LY, Chen Y, Ren GS, Tao Q.

Chin J Cancer. 2013 Jan;32(1):12-20. doi: 10.5732/cjc.011.10344. Epub 2011 Nov 4. Review.

17.

Detection of aberrant methylation of a six-gene panel in serum DNA for diagnosis of breast cancer.

Shan M, Yin H, Li J, Li X, Wang D, Su Y, Niu M, Zhong Z, Wang J, Zhang X, Kang W, Pang D.

Oncotarget. 2016 Apr 5;7(14):18485-94. doi: 10.18632/oncotarget.7608.

18.

Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer.

Moelans CB, Verschuur-Maes AH, van Diest PJ.

J Pathol. 2011 Oct;225(2):222-31. doi: 10.1002/path.2930. Epub 2011 Jun 27. Erratum in: J Pathol. 2012 Jan;226(1):143.

PMID:
21710692
19.

Methylation analysis of plasma cell-free DNA for breast cancer early detection using bisulfite next-generation sequencing.

Li Z, Guo X, Tang L, Peng L, Chen M, Luo X, Wang S, Xiao Z, Deng Z, Dai L, Xia K, Wang J.

Tumour Biol. 2016 Oct;37(10):13111-13119. Epub 2016 Jul 23.

PMID:
27449045
20.

Methylation profiling of 48 candidate genes in tumor and matched normal tissues from breast cancer patients.

Li Z, Guo X, Wu Y, Li S, Yan J, Peng L, Xiao Z, Wang S, Deng Z, Dai L, Yi W, Xia K, Tang L, Wang J.

Breast Cancer Res Treat. 2015 Feb;149(3):767-79. doi: 10.1007/s10549-015-3276-8. Epub 2015 Jan 31.

PMID:
25636590

Supplemental Content

Support Center